TY  - JOUR
AU  - MAFFEZZOLI, MICHELE
AU  - GIUDICE, GIULIA CLAIRE
AU  - IOVANE, GIACOMO
AU  - MANINI, MARTINA
AU  - RAPACCHI, ELENA
AU  - CARUSO, GIUSEPPE
AU  - SIMONI, NICOLA
AU  - FERRETTI, STEFANIA
AU  - PULIATTI, STEFANO
AU  - CAMPOBASSO, DAVIDE
AU  - BUTI, SEBASTIANO
PY  - 2025
TI  - The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative review
JO  - Oncology Research
SN  - 0965-0407
SP  - 741
EP  - 757
VL  - 33
IS  - 4
AB  - Backgroundimmune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic urothelial carcinoma (mUC), significantly improving survival outcomes. However, a subset of patients do not respond to ICIs, prompting research into potential predictive factors. Commonly prescribed medications such as corticosteroids, proton-pump inhibitors (PPIs), antibiotics (Abs), antihypertensives, and analgesics may influence ICI effectiveness. Methodswe conducted a literature search on PubMed to investigate the impact of concomitant medications on the outcomes of patients with mUC, treated with ICIs. We selected the most relevant studies and performed a narrative review. Resultscorticosteroids, PPIs and Abs have been associated with reduced survival in ICI-treated patients, including those with mUC. In contrast, antihypertensive agents like renin-angiotensin system inhibitors and beta-blockers may enhance ICI efficacy, though evidence remains inconclusive. The impact of other medications, such as statins, metformin, and analgesics, on ICI outcomes is less clear, with some data suggesting a detrimental impact on immune response.Conclusionsthis narrative review synthesizes current evidence on how concomitant medications affect outcomes in mUC patients treated with ICIs.
UR  - https://doi.org/10.32604/or.2024.057278
DO  - 10.32604/or.2024.057278